Tissue-free Guardant Reveal test identifies disease progression up to 18 months earlier than standard clinical measures in patients with advanced cancer Longitudinal circulating tumor DNA (ctDNA) ...

・Guardant Health’s Q3 revenue surged 39% year-over-year to $265.2 million, led by strong growth in its oncology, screening, and biopharma segments. ・The company raised its 2025 revenue guidance to as ...

Guardant Health handily beat Q1 expectations and meaningfully increased full-year growth expectations. Guardant also continues to benefit from positive developments in relation to pricing, regulatory ...

Guardant Health has continued a revenue increase as showcased in the last earnings report, growing 17% YoY. GH stock is part of a large industry that has high CAGR estimates, but investors are yet to ...

More than three years into a lawsuit accusing competitor Natera of disparaging its cancer blood test, Guardant Health has emerged victorious. As both companies reported Monday, a federal jury in the U ...

PALO ALTO, Calif., November 04, 2025--(BUSINESS WIRE)--Guardant Health, Inc. ("Guardant Health") (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 ...

Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company’s full-year revenue guidance of $920 million at the midpoint came in 3.9% ...

Guardant Health (NASDAQ:GH) presented an optimistic outlook at the Jefferies London Healthcare Conference 2025, held on Wednesday, 19 November. The company highlighted strong Q3 performance and ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with Epic, the nation’s most widely used comprehensive ...

Developing an entirely new cancer drug from scratch is a notoriously complex and time-consuming process, with drugmakers taking years to produce a single candidate that may or may not ever make its ...